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Purpose: The translation of genome sequencing into routine
health care has been slow, partly because of concerns about
affordability. The aspirational cost of sequencing a genome is
$1000, but there is little evidence to support this estimate. We
estimate the cost of using genome sequencing in routine clinical
care in patients with cancer or rare diseases.
Methods: We performed a microcosting study of Illumina-based
genome sequencing in a UK National Health Service laboratory
processing 399 samples/year. Cost data were collected for all steps
in the sequencing pathway, including bioinformatics analysis and
reporting of results. Sensitivity analysis identified key cost drivers.
Results: Genome sequencing costs £6841 per cancer case
(comprising matched tumor and germline samples) and £7050
per rare disease case (three samples). The consumables used during
sequencing are the most expensive component of testing (68–72%
of the total cost). Equipment costs are higher for rare disease cases,
whereas consumable and staff costs are slightly higher for
cancer cases.
Conclusion: The cost of genome sequencing is underestimated if
only sequencing costs are considered, and likely surpasses $1000/
genome in a single laboratory. This aspirational sequencing cost
will likely only be achieved if consumable costs are considerably
reduced and sequencing is performed at scale.
Genetics in Medicine (2020) 22:85–94; https://doi.org/10.1038/s41436-
019-0618-7
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INTRODUCTION
Next-generation sequencing (NGS) technologies provide
high-throughput simultaneous testing of multiple genes and
allow either the whole genome or parts of it (via exome
sequencing or targeted panels) to be sequenced in hours, at
great depth and increasing sensitivity. These technologies
have been in use, largely on a research basis, since 2008. Prior
to 2008, the use of Sanger-based technologies meant that
resequencing was substantially more expensive—for example,
a human genome cost an estimated $20–25 million in 2006.1
With the advent of NGS, there has been a significant and
ongoing decline in consumable costs, hence there is wide-
spread expectation that a “$1000 genome” may soon be
available. However, this expectation likely only reflects the
consumables component and does not consider the overall
costs of the sequencing process, which include sample
processing (including library preparation and sequencing),
bioinformatic data processing and analysis, interpretation and
reporting of sequencing results, and data storage. Clinical
interpretation in particular can be lengthy and costly. This
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dichotomy has led to descriptions of “the $1000 genome and
the $100,000 analysis.”2
To ensure that NGS technologies are not merely an
expensive addition to patient care, demand is increasing for
accurate figures on the “complete” costs of the entire
sequencing process. There is considerable variation in the
costs reported in academic papers and the media. A review of
economic evaluations of exome and genome sequencing in
2018 reported that cost estimates for a single test ranged from
£382 ($555) to £3592 ($5169) for exome sequencing and from
£1312 ($1906) to £17,243 ($24,810) for genome sequencing.3
Few cost analyses presented data transparently, and many
publications did not state which components were included in
cost estimates. In addition, resource use and unit costs were
rarely reported in a disaggregated manner, and many studies
did not calculate the actual cost of exome or genome
sequencing, instead using prices charged by commercial
operators. Furthermore, few studies have accounted for the
number of samples that realistically must be sequenced to
achieve a diagnostic result; at least two samples are required
for cancer cases and three are often required for rare disease
cases, with the proband and both parents often sequenced as
a trio.
This paper reports a microcosting study that we undertook
to provide comprehensive and detailed estimates of the
complete costs of using genome sequencing to identify
pathogenic variants. This study was undertaken in the context
of routine care for patients with cancer or rare diseases in one
National Health Service (NHS) laboratory in the United
Kingdom (UK).
MATERIALS AND METHODS
We undertook a detailed microcosting study of clinical-grade
genome sequencing using the Illumina HiSeq 4000 in the
Oxford Molecular Diagnostics Center (OMDC), an accredited
NHS laboratory in the UK. Although clinical grade, genome
sequencing is not yet routine in NHS clinical practice and the
sequencing described herein was funded as part of a
translational research grant. Microcosting is a highly detailed
health economic costing approach in which all of the
underlying resources required for an intervention or activity,
such as equipment, consumables, and staff time, are
identified, and then unit costs are attached to this resource
use to generate an overall cost. This microcosting study was
undertaken in line with the methods outlined by Drummond
et al.,4 and was carried out from June 2016 to December 2017.
Patient and participant recruitment
Patients with rare diseases or cancers suitable for genome
sequencing were referred for sequencing via participating
clinicians. Rare disease referrals were triaged at a Genomic
Medicine Multi-Disciplinary Team (MDT) meeting, based on
whether prior genetic testing for known genes (panel tests
and arrays) had been carried out (and found to be normal).
Pediatric and adult patients with a broad spectrum of
rare disease (including developmental, neurological,
immunological, cardiovascular, and musculoskeletal condi-
tions) were recruited. Family trios comprising the proband
and both parents were recruited where possible, since
knowledge of the genetic variants and affection status of
parents allows many variants to be eliminated in the filtering
process. Based on our experience, this greatly improves the
success rate for identifying pathogenic variants while reducing
analysis time.5
Cancer cases were also reviewed at an MDT meeting for
suitability for genome sequencing. Patients with a broad
spectrum of cancer types were recruited, including breast,
colorectal, prostate, and endometrial cancers. Tumor and
germline DNA samples were obtained for each patient;
however, tumor sequencing was only undertaken if the
pathologist’s report indicated that >40% of the tissue was
tumor. Following sequencing, somatic variants were identified
by subtraction of the germline variants from those in
the tumor.
Genome sequencing pathway
We first determined the precise testing pathway for genome
sequencing in the OMDC laboratory. The standard operating
procedures for the HiSeq 4000 (Illumina Inc., San Diego, CA)
were used to develop costing questionnaires to collect
resource use information. These questionnaires were com-
pleted by staff at the Oxford Biomedical Research Center
(a public partnership between the University of Oxford and
Oxford University Hospitals NHS Foundation Trust, funded
by the National Institute for Health Research). All steps in the
genome sequencing pathway, from sample reception to data
interpretation, reporting, and archiving were considered (see
Supplementary Materials—Part 1 for a detailed description of
the pathway and methods). Questionnaire responses indicated
that the same stages appeared in both the rare disease and
cancer pathways (Fig. 1).
The bioinformatics phase included both clinical and
research bioinformatics. Clinical bioinformatics analysis,
which all samples passed through, consisted of a standardized
pipeline to identify variants in genes known to be pathogenic
for the presenting condition (see Supplementary Materials—
Part 2 for details of all software packages used). For cancer
cases, variants were classified as tier 1, 2, or 3 according to Li
et al. and clinically actionable variants were reported.6 Read
mapping and alignment were carried out in a similar manner
for rare diseases. Annotation of rare disease variants was
based on American College of Medical Genetics and
Genomics (ACMG) guidelines.7 Variants classified as patho-
genic, likely pathogenic, and of uncertain significance within
the in silico panels were detailed in a clinical report.
Secondary findings were also investigated in any patients or
participants who had consented to this, by applying a 50-gene
in silico panel as recommended by the ACMG.8–10
For rare disease cases where variants were not identified in
known pathogenic genes for the presenting condition, we
explored all genomic variants passing quality control filters
and fitting the inheritance pattern and clinical features. This
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analysis was specific to each individual case, dependent on its
complexity, duration of analysis, and requirement for
functional validation studies to confirm pathogenicity. These
investigations were considered within a research bioinfor-
matics phase in this analysis, and not included in the base case
costing.
At the end of the genome sequencing pathway, the results of
the data analysis were reported to the referring clinician, and
the sequencing data and results were archived using Arkivum
(London, UK). This provided industry standard encryption,
offsite storage at multiple locations, and near disk retrieval
speeds.
Resource use and unit costs
Data were collected on resource use and unit costs for each
step in the pathway. This included the average staff time for
each activity and salary data, use of equipment (initial costs,
maintenance costs, and proportion of time used for genome
sequencing diagnostics, for both computing and laboratory
equipment) and consumables (laboratory supplies, software
licenses, service contracts) and error rates. Resource use data
were adjusted to reflect the different requirements of genome
sequencing in cancer and rare diseases. In cancer cases, two
DNA samples were sequenced—one extracted from the tumor
tissue (TT), which required a sequencing depth of at least 75×,
and one germline sample at a minimum of 30× depth. This
meant that in the sequencing and bioinformatics stages, TT
samples required different quantities of consumables com-
pared with germline samples. For rare disease trios, three
samples were sequenced (the proband and both parents), each
at a minimum of 30× depth.
The resources that were used were then linked to their
associated unit costs. Unit cost data was extracted from OMDC
purchasing records where possible. If this was not possible, unit
costs were obtained from commercial laboratory equipment
suppliers. When cost data were only available for a kit as a
whole, kit costs were apportioned equally across all items in the
kit. Costs that were specified in US dollars were converted to
British pounds based on the average exchange rate of $1.23:£1
in November 2016. All comparator costs reported for other
studies are also presented in 2016 values (https://www.gov.uk/
government/col-lections/exchange-rates-for-customs-and-vat).
The most expensive item was the HiSeq 4000 sequencing
machine (Illumina), which cost £474,373, with an annual
maintenance cost of £55,641. This sequencing system requires
two consumable kits (a HiSeq 3000/4000 Sequencing by
Synthesis [SBS] Kit costing £4207 and a HiSeq 3000/4000
Paired End [PE] Cluster Kit costing £2597), with half of each
kit required per case.
Sequencing data and results were assumed to be archived in
variant call format (VCF) files for five years at the end of the
genome sequencing pathway. Rare disease samples were
assumed to require 0.4 GB of storage space each year (i.e., 1.2
GB/year for a trio). For cancer, germline samples were
assumed to require 0.4 GB per year and subtracted tumor
samples were assumed to require 1 GB per year.
Information on staff salaries was extracted from national
salary scales from March 2016 for NHS staff and from
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Fig. 1 Genome sequencing testing pathway for cancer and rare
disease cases in the Oxford Molecular Diagnostics Center. The arrows
on the right-hand side indicate the potential for stage repetition due to
minor process errors.
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University of Oxford salary scales for the year 2016 for
university staff (see Supplementary Materials—Part 2 for
details). The midpoints of salary ranges were used, a working
year was assumed to be 44 weeks, and a working week was
assumed to be 37.5 hours. All salaries were inflated by 20% to
incorporate National Insurance and superannuation.
Sample throughput and error rates
The number of rare disease and cancer cases processed per
year was assumed to be 224, which equated to 399 samples.
This assumption was based on actual throughput at the
OMDC between 1 April and 25 November 2016 (see
Supplementary Materials—Part 2 for details). A small number
of samples were assumed to repeat specific stages of the
testing process, depending on step-specific error rates (see
Supplementary Materials—Part 2 for details). These error
rates have reduced over time, as experience of achieving
optimal cluster density has been gained.
Additional costing considerations
The costs of equipment items were discounted at a rate of
3.5% over a lifespan appropriate to each item. Lifespans were
based on information provided by laboratory staff. If no
information was available, a lifespan of five years was
assumed. If maintenance costs were incurred for equipment
items, these were included. Both equipment costs and
maintenance costs were weighted by the percentage of time
that a piece of equipment was used for genome sequencing.
Sample batching was incorporated into cost calculations. As
per UK guidance, value-added tax (VAT) was excluded.11
Total costs were inflated by an additional 20% to account for
overheads, which include items such as general hospital
administration, cleaning, and electricity. Further details on all
resource use that was costed in this study are provided in
Tables S5–S10 (Supplementary Materials—Part 3). In total,
we costed 98 consumable items and 132 equipment items for
cancer cases, and 86 consumable items and 125 equipment
items for rare disease cases.
Sensitivity analysis
Sensitivity analysis was performed to explore the structural
and methodological uncertainty in this microcosting study
and to assess how changes in key variables would affect test
costs. This ensures that our results are more generalizable to
other settings. Discount rates of 1.5% and 5% were evaluated,
as per UK recommendations,11 as well as the inclusion of
VAT calculated at 20%. Other parameters that were varied
included the overhead rate, all inputs to staff cost calculations,
the length of data archiving, kit costs, and the cost of the
HiSeq 4000, whether or not rare disease cases required
research bioinformatics, the size of rare disease cases, and
error rates. We also evaluated the impact of archiving binary
alignment map (BAM) files alongside VCF files. For both
cancer and rare disease cases we assumed that this would
require 150 GB of storage per year. Finally, annual throughput
was varied between 100 and 2000 samples, and we tested the
joint impact of both a reduction in consumable costs and an
increase in sample throughput. Annual throughput of
1000 samples was tested in this analysis as this was the
projected annual capacity of the HiSeq 4000 sequencing
machine in this OMDC setting. The effect of increasing
throughput to 2000 samples was also investigated to assess
whether costs plateau when volume increases.
RESULTS
Cancer
Table 1 reports the costs per stage of genome sequencing for a
cancer case (tumor and germline sample). The total cost of
Table 1 Cost of genome sequencing for a cancer case (tumor and germline sample)
Stage Cost category Total % Total test costs before
overheadsEquipment Consumables Staff
Sample reception £0.24 £0.31 £17.59 £18.14 0.3%
DNA extraction £0.19 £20.91 £15.95 £37.06 0.7%
Nanodrop £0.16 £0.11 £6.20 £6.47 0.1%
Qubit £0.19 £3.05 £11.20 £14.43 0.3%
Agarose gel £0.15 £14.26 £22.70 £37.11 0.7%
Library processinga £51.83 £132.09 £84.64 £268.56 4.7%
Sequencingb £615.24 £3688.04 £48.55 £4351.83 76.3%
Bioinformatics £1.80 £266.73 £406.99 £675.52 11.8%
Reporting £0.00 £0.00 £257.25 £257.25 4.5%
Data archiving £24.56 £0.96 £8.83 £34.35 0.6%
Total (before overheads) £694.35 £4126.46 £879.89 £5700.71 -
% total cost 12% 72% 15% - -
Total (including overheads calculated
at 20%)
- - - £6840.85 (£3420.43 per
genome)
-
aLibrary processing includes library preparation, normalization, and validation.
bSequencing also includes clustering.
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genome sequencing for a cancer case is £6841 (£3420 per
genome). Consumables account for 72% of this cost (before
overheads). Three-quarters (76%) of the costs of genome
sequencing are accrued in the sequencing stage. Equipment
costs for this stage are £615. Almost all of this cost relates to
the sequencer, which costs £564 per case. Consumable costs
are also high for this stage (£3688). These costs primarily
relate to the use of a HiSeq SBS kit, which costs £2265 per
case. The HiSeq PE kit is also a notable cost driver, costing
£932 per case. The only other stage that contributes more
than 10% of the total cost of genome sequencing is
bioinformatics and clinical interpretation (12%). Consum-
ables cost £267 for this stage. The main cost driver is
BaseSpace Enterprise, costing £155 per case. Staff costs are
higher, at £407. This is the cost associated with the use of 923
minutes (15 hours 23 minutes) of clinical scientist time per
case.
Rare diseases
Table 2 reports the costs per stage of genome sequencing for a
rare disease case (three samples). The total cost of genome
sequencing such a trio is £7050 (£2350 per genome).
Consumables account for 68% of this cost (before overheads).
Similar to cancer cases, most of the costs of genome
sequencing (79%) are accrued in the sequencing stage.
Consumables cost £3688 for this stage (exactly the same cost
as for cancer testing), with most of this cost again relating to
the use of a HiSeq SBS kit (£2265 per case) and a HiSeq PE kit
(£932 per case). Equipment costs total £923 for this stage,
with almost all of this cost (£846) relating to the sequencer, as
per the cancer costing. A further 7% of total costs are accrued
in the bioinformatics stage. Staff time costs £313 for this stage.
This is the cost associated with the use of 714 minutes
(11 hours 54 minutes) of clinical scientist time per case.
Comparing the costs for cancer and rare diseases
The use of genome sequencing as a diagnostic tool is £209
more expensive in rare diseases cases compared with cancer
cases. Equipment costs are higher for rare disease cases than
for cancer cases, reflecting differences in the number of
samples sequenced per case and sequencing depth. Con-
sumable and staff costs are, however, slightly higher for
cancer cases. Staff costs are higher during the clinical
interpretation stage for testing in cancer (£407, compared
with £313 for rare disease cases) due to differences in
clinical scientist time during this stage (923 minutes for
cancer; 714 minutes for rare diseases), which reflects the fact
that investigation of variants in previously undescribed
genes is not included in the base case cost for rare disease
cases (while only known cancer genes are included in the
clinical analysis, their contributions to specific tumors often
requires further investigation of the literature).
The difference in consumable costs is driven by lower
software costs for rare disease cases during the bioinfor-
matics stage (£113, compared with £267 for cancer cases),
again because consumables for investigation of variants in
previously undescribed genes are not included in the base
case cost for rare disease cases. Sequencing consumable
costs were identical for rare disease and cancer cases
because the same number of clustering and sequencing kits
were used to sequence a rare disease trio (three samples at
minimum 30× coverage) as a cancer case (with tumor and
germline at minimum coverage of 75× and 30× respec-
tively). Although this introduced some wastage for rare
disease cases, this approach was necessary to achieve the
rapid turnaround required for clinical cases. Such costs
could be reduced in a high-volume facility where samples
could be more effectively batched. Although equipment
costs are £348 higher for rare disease cases (as 1.5× as many
Table 2 Cost of genome sequencing for a rare disease trio case (three samples)
Stage Cost category Total % Total test costs before
overheadsEquipment Consumables Staff
Sample reception £0.35 £0.76 £21.90 £23.01 0.4%
DNA extraction £0.64 £1.38 £5.72 £7.74 0.1%
Nanodrop £0.24 £0.17 £7.16 £7.56 0.1%
Qubit £0.28 £3.53 £17.33 £21.14 0.4%
Agarose gel £0.23 £16.37 £23.27 £39.87 0.7%
Library processinga £77.75 £197.55 £117.34 £392.64 6.7%
Sequencingb £922.86 £3688.04 £48.55 £4659.45 79.3%
Bioinformatics £2.69 £113.33 £313.22 £429.25 7.3%
Reporting £0.25 £0.00 £247.69 £247.94 4.2%
Data archiving £36.85 £0.82 £8.83 £46.49 0.8%
Total (before overheads) £1042.13 £4021.95 £811.01 £5875.09 -
% total cost 18% 68% 14% - -
Total (including overheads calculated
at 20%)
- - - £7050.11 (£2350.04 per
genome)
-
aLibrary processing includes library preparation, normalization, and validation.
bSequencing also includes clustering.
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Table 3 One-way sensitivity analysis results
Parameter (base case value) Variation Genome sequencing for cancer Genome sequencing for rare
diseases
Cost % Change vs.
base case
Cost % Change vs.
base case
Base case analysis - £6840.85 - £7050.11 -
Annual sample throughput (399 samples) 100 £9499.91 39% £10,804.71 53%
200 £7726.24 13% £8300.28 18%
500 £6662.04 −3% £6797.63 −4%
750 £6425.56 −6% £6463.70 −8%
1000 £6307.31 −8% £6296.74 −11%
2000 £6129.95 −10% £6046.30 −14%
National Insurance/superannuation multiplier (20%)a 10% £6752.86 −1% £6971.89 −1%
30% £6928.84 1% £7128.33 1%
Weeks worked per year (44)b 40 £6946.44 2% £7143.97 1%
50 £6714.15 −2% £6937.47 −2%
Hours worked per week (37.5)b 30 £7104.82 4% £7284.77 3%
45 £6664.87 −3% £6893.67 −2%
Overheads (20%) 10% £6270.78 −8% £6462.60 −8%
30% £7410.92 8% £7637.62 8%
Discount rate (3.5%) 1.5% £6799.67 −1% £6988.30 −1%
5.0% £6873.08 0% £7098.47 1%
VAT (excluded) Included £7901.69 16% £8215.43 17%
BAM files archived? (no) Yes £6962.87 2% £7172.29 2%
Years of data archiving (5) 3 £6840.39 0% £7049.71 0%
10 £6842.00 0% £7051.09 0%
Research bioinformatics Excluded £6679.23 −2% Based -
Included Basec - N/A -
Standard case N/A - £7593.67 8%
Intermediate case N/A - £7582.82 8%
PE kit cost (£2597) 50% £6001.71 −12% £6210.96 −12%
150% £7680.00 12% £7889.25 12%
SBS kit cost (£4207) 50% £5481.61 −20% £5690.86 −19%
150% £8200.10 20% £8409.35 19%
Sequencing machine cost (£474,373) 50% £6669.46 −3% £6793.01 −4%
150% £7012.25 3% £7307.20 4%
Family size for rare disease cases (3) 2.4 N/A - £5650.39 −20%
2.6 N/A - £6116.96 −13%
2.8 N/A - £6583.53 −7%
Error rate—library processing (5%) 2.5% £6834.66 0% £7041.41 0%
7.5% £6847.05 0% £7059.10 0%
Error rate—clustering (15%) 5% £6838.92 0% £7048.18 0%
25% £6842.78 0% £7052.04 0%
Error rate for the sequencing by synthesis and paired end
kits (7.7%)
4% £6690.20 −2% £6899.45 −2%
12% £7016.82 3% £7226.08 2%
Error rate—sequencing (25%) 15% £6835.57 0% £7044.83 0%
35% £6845.95 0% £7055.20 0%
BAM binary alignment file, PE paired end, SBS sequencing by synthesis, VAT value-added tax.
aNational Insurance is a UK tax that funds state benefits. As this is an expense that is directly incurred by employers (rather than a transfer payment), this cost is typically
included in economic evaluations and microcosting studies.
bThroughput held constant in this sensitivity analysis. Hourly wage rates were generated for our analysis by combining data on annual staff salaries with assumptions
regarding weeks worked per year and hours worked per week. As hourly wage rates (and thus our overall cost estimates) naturally varied when these assumptions were
varied, we evaluated variations in these parameters in our sensitivity analysis.
cThe base case analysis for cancer includes research bioinformatics costs as these costs are relatively few (£134.69). This calculation assumes that for cancer, severity of
case does not impact on research bioinformatics costs.
dThe base case analysis for rare diseases does not include research bioinformatics costs as these costs are more substantial and variable. Costs are instead provided for a
standard case, requiring 120 minutes of staff time, and a case of intermediate difficulty, requiring 300 minutes of staff time.
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samples are required), this is balanced out by higher
consumable and staff costs for cancer testing.
Figure S1 (Supplementary Materials—Part 4) shows the
proportion of test costs accrued in each testing stage for
cancer and rare disease cases. Library processing (6.7% vs.
4.7%) and sequencing (79.3% vs. 76.3%) account for a greater
proportion of genome sequencing costs for rare diseases cases
compared with cancer cases. Conversely, bioinformatics
(11.8% vs. 7.3%) accounts for a greater proportion of genome
sequencing costs for cancer cases compared with rare
diseases cases.
Sensitivity analysis
The results of the sensitivity analysis are presented in Table 3.
Changes in several variables had a notable impact on the
costing results. A reduction in HiSeq 4000 annual sample
throughput from 399 samples to 100 samples increased the
cost of cancer genome sequencing by 39% to £9500 per case,
and increased the cost of rare disease genome sequencing by
53% to £10,805 per case. Increasing annual sample through-
put to 1000 (the projected annual capacity of the HiSeq 4000
in this setting) reduced the cost of cancer genome sequencing
and rare disease genome sequencing by 8% and 11%,
respectively. Holding all other variables constant (for
example, assuming no bulk discount on consumable costs),
the reduction in sequencing costs that naturally occurs as
throughput increases hits a floor at approximately £5950 for
cancer cases (£2975 per genome) and £5796 (£1932 per
genome) for rare disease cases.
Most changes in staff-related variables had a negligible
effect on the cost of testing, as did changes in the discount
rate. Including the costs of research bioinformatics for rare
disease cases has a significant impact on the cost of testing.
Both standard cases and cases of intermediate difficulty
increase test costs by 8%, to £7594 and £7583 per case,
respectively (intermediate cases require more staff time than
standard cases—300 minutes per case versus 120 minutes—
but require software with lower licensing costs). Varying the
PE and SBS consumables kit costs by 50% above and below
the base case values impacted on both test costs, but did not
change the cost difference between the two testing applica-
tions. Varying the cost of the sequencer by 50% above and
below the base case value changed both test costs by a
negligible amount, primarily because half of the sequencer
cost per cancer or rare disease case (£279 for cancer cases and
£418 for rare disease cases) is the annual maintenance cost for
the sequencer, not the cost of the sequencer itself. Archiving
BAM files as well as VCF files increased the cost per case by
just 2% for both cancer and rare disease cases.
The full results of the joint sensitivity analysis on
throughput and consumable costs are presented in Figures S2
and S3 (Supplementary Materials—Part 5) for genome
sequencing in cancer and genome sequencing in rare diseases
(with results expressed as the cost per case). Figure 2 presents
the results of this analysis for genome sequencing in rare
diseases in terms of the change in cost per genome. With an
increase in annual throughput from 399 to 2000 samples, and
a reduction in consumable costs from £1341 per genome to
£33 per genome, the cost per genome falls from £2350 to
£447.
DISCUSSION
This paper reports the first detailed cost analysis for the
complete genome sequencing process for both cancer and rare
disease cases in a single center within the UK NHS. Our
results show that the costs of using genome sequencing as a
diagnostic tool are similar for both cancer (£6841 per case or
£3420 on average per genome) and rare disease cases (£7050
per trio or £2350 per genome). Using a medium throughput
sequencer (the HiSeq 4000), the key cost drivers for cancer
cases are sequencing (£4352 per case, of which £3688 is for
consumables) and, to a lesser extent, bioinformatics and
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reporting (£933). The key cost drivers for rare disease cases
are the same: sequencing (£4659 per case) and bioinformatics
and reporting (£677).
Although our cost estimates are similar for cancer and rare
disease cases, there are some small differences in the types of
costs incurred in each context based on the fact that a cancer
case is considered here as two samples (tumor and germline)
and a rare disease case as a trio (parents and proband). While
two samples are a necessity for cancer cases to identify
pathogenic variants in the tumor, a rare disease case could
yield diagnostic results from the proband’s genome alone.
However, based on our experience this considerably reduces
the success rate for identifying pathogenic variants while also
contributing substantially to analysis time and costs.5 Hence
our policy has been to recruit rare disease trios. In this regard,
it should be noted that the 100,000 Genomes Project in the
UK has also elected to preferentially recruit trios for its rare
disease cases. While proband-only testing is increasingly
being used in some countries as an in silico panel that can be
flexibly applied to multiple disorders, this restricts the
potential for molecular diagnoses to those in previously
identified disease genes, and makes identification of novel
genes or genotype/phenotype associations unlikely.
Our cost estimates are generally lower than those reported
in previous studies when considered on a per patient genome
basis (the costs of also testing parents were not included in
other studies).3 A Canadian microcosting study of genome
sequencing in autism spectrum disorder cases estimated the
cost of testing to be £3016 (US $4346) for a single patient
sample using the Illumina HiSeq 2500 (95% confidence
interval: £2866 to £3161).12 In this study, follow-up with
Sanger sequencing for the proband and two parents was
assumed to take place in 50% of cases, costing £98 (US $141)
per sample (95% confidence interval: £86 to £110). A similar
estimate was reported by Christensen et al. in 2018. This US
study reported the results of randomized controlled trials of
genome sequencing in two settings, estimating the costs of
testing per patient to be £3673 (US $5338) in a cardiology
setting and £3641 (US $5291) in a primary care setting.13
These figures included the cost of confirmatory Sanger
sequencing in the proband, which ranged from £420 to
£435 (US $611 to $632) per patient. Another Canadian study
by Weymann et al. reported a much higher cost for the
Illumina HiSeq 2500. This study estimated the costs of using
genome sequencing and subsequent analysis to guide
treatment decisions in advanced cancers, reporting a cost
per patient of £10,820 (US $15,727; 95% confidence interval:
£10,264 to £11,375) but it additionally included biopsy and
tissue sample processing, RNASeq, panel testing, and
experimental verification.14 A final Canadian microcosting
study of genome sequencing in autism spectrum disorder
estimated the cost of testing to be £1168 (US $1696) per
genome when a trio was tested using the Illumina HiSeq X
platform (95% confidence interval: £1118 to £1217).15 The
annual cost of follow-up using Sanger sequencing, fluores-
cence in situ hybridization (FISH), and quantitative
polymerase chain reaction (qPCR) tests in probands and
their parents ranged from £46 to £51 ($66 to $75).
Our study contributes to this evidence base by presenting
highly detailed cost estimates in two clinical contexts,
providing full information on which components were
included in these estimates. We also calculate the actual cost
of genome sequencing, in contrast to previous studies that
have presented a commercial price. Going forward, these cost
estimates will be a useful input into economic modeling
studies that underpin health technology assessments of
genome sequencing, and will help to inform budgetary
calculations at both the local and national level. These
estimates will also be informative when determining the
optimal positioning of genome sequencing in diagnostic
pathways. This is a particular concern in the context of rare
diseases, as these disorders are commonly characterized by
diagnostic odysseys. Finally, in the UK standardized unit costs
exist for many elements of health-care resource use in the
form of NHS reference costs, for example.16 However, there
are no national tariffs for genome sequencing.17 These cost
estimates will help to fill that gap in the literature.
Several limitations of our study should, however, be
noted. First, costs were calculated for the Illumina HiSeq
4000. It is therefore unclear how our estimates relate to the
costs associated with alternative sequencing platforms,
particularly those with higher throughput. However, as
our costs are provided at a highly detailed level this should
facilitate comparisons with other sequencing platforms.
Second, these costs were estimated in a UK setting, so may
not be directly generalizable to other country settings.
However, these estimates may be broadly indicative of the
magnitude of these test costs in other settings. Furthermore,
the sequencing consumables unit costs are likely to be
similar between countries; the discounts that are provided
for bulk orders are likely to be a more significant factor in
influencing cost. Studies that estimate genome sequencing
costs at a similarly detailed level in other countries are
urgently required, as well as studies that consider whether
these cost estimates might vary in cancer or rare disease
subgroups. Third, our cost estimates are based on unit costs
from 2016. These unit costs will likely be different in 2019,
however it was not possible to source new quotes from
suppliers to update these costs. Fourth, we included the cost
of overheads in our estimates by assuming that these costs
were equal to 20% of the total cost of testing. This approach
implies that the overheads that are attributable to sequen-
cing are proportional to the overall cost of sequencing.
Given that consumables accounted for a large proportion of
sequencing costs in both cancer and rare disease cases, this
assumption may not hold. Fifth, our analysis assumed a
minimum sequencing depth of 75× for tumor samples, 30×
for germline samples, and 30× for probands and parents
sequenced as part of a rare disease trio. It was not possible
to vary these assumptions in sensitivity analysis to estimate
to what extent the cost of sequencing increases if sequencing
depth also increases. Finally, the moratorium on the use of
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non-UK cloud-based storage for NHS patient data during
the study period forced us to use a UK-based archiving
service (Arkivum). As there are now other cloud storage
options in the UK, it is possible that storage costs will be
lower. However, data archiving was not a key cost driver for
either application of genome sequencing.
Our results have implications for policymakers, both in the
UK and in other countries. Our microcosting study was
undertaken in a single laboratory processing ~400 genome
sequencing samples per year, so explored the impact on cost
of varying sample throughput in a single center. Lower costs
are, however, likely to be achievable if genome sequencing is
rolled out as a routine test in clinical practice at the national
level, realizing economics of scale in terms of equipment costs
and providing access to bulk discounts on consumable costs.
Indeed, the “$1000 genome” may already be achievable in
such a system if only sequencing consumable costs are
considered. Future work evaluating the costs of sequencing at
scale (particularly the link between the use of high-
throughput sequencing platforms, sample throughput, and
reductions in consumable costs) would help to inform
decision-making at the national level regarding the appro-
priate configuration of sequencing services. This work is
particularly relevant given the recent completion of the
100,000 Genomes Project in England and the launch of a new
Genomic Medicine Service in the UK NHS.18 The combina-
tion of bioinformatics and reporting was the second most
expensive step in the testing pathway, although these costs
were much lower than those associated with the sequencing
step. Further automation of the bioinformatics pipeline and
streamlining of clinical reporting may reduce these costs
somewhat going forward, at both the single center and
national scale. However, bioinformatics and reporting costs as
a proportion of overall sequencing costs may increase in the
short to medium term, if automation and a reduction in
sequencing consumable costs due to sequencing at scale
happen at the same time. Finally, our analysis did not
consider the cost of any actions taken on the basis of genome
sequencing test results, such as changes in patient clinical
management. Future work should explore and quantify these
potentially significant downstream costs.
Conclusions
Our findings suggest that the costs of genome sequencing
and clinical analysis of a cancer case or rare disease trio are
£6841 (£3420 per genome) and £7050 (£2350 per genome),
respectively. The costs of sequencing are yet to meet the
desired $1000 per genome figure when testing is performed
on relatively small numbers of patients with cancer or a rare
disease in a single center with modest throughput.
Sensitivity analyses indicate that high throughput—com-
mensurate with a national-scale facility—combined with
bulk discounts on consumable costs will likely have the
greatest impact on the overall cost of sequencing going
forward. This will be an important consideration for
policymakers in this arena.
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